IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance

David H. Munn, Andrew L. Mellor

Research output: Contribution to journalReview article

210 Citations (Scopus)

Abstract

Indoleamine 2,3-dioxygenase (IDO) has immunoregulatory roles associated with tryptophan metabolism. These include counter-regulation (controlling inflammation) and acquired tolerance in T cells. Recent findings reveal that IDO can be triggered by innate responses during tumorigenesis, and also by attempted T cell activation, either spontaneous or due to immunotherapy. Here we review the current understanding of mechanisms by which IDO participates in the control of inflammation and in peripheral tolerance. Focusing on the tumor microenvironment, we examine the role of IDO in response to apoptotic cells and the impact of IDO on Treg cell function. We discuss how the counter-regulatory and tolerogenic functions of IDO can be targeted for cancer immunotherapy and present an overview of the current clinical progress in this area. IDO can be induced in the tumor microenvironment by the spontaneous inflammation and T cell activation associated with many tumors; however, IDO may also be induced reactively, in response to inflammation induced by antitumor immunotherapy.IDO is rapidly induced when mice are challenged with apoptotic cells. Inhibiting or genetically deleting IDO results in loss of self-tolerance to apoptotic cell-associated antigens, and susceptibility to lupus-like autoimmunity.DNA-containing nanoparticles can induce immunosuppressive IDO via a pathway dependent on the STING sensor of cytosolic DNA.When Treg cells are activated in the presence of IDO, they upregulate a highly suppressive phenotype driven by the PTEN lipid phosphatase. In vivo, challenge with apoptotic cells triggers IDO-mediated induction of PTEN-expressing Treg cells.In tumors, IDO induction by apoptotic cells may become relevant as the tumor attempts to inhibit immune responses to dying tumor cells following chemotherapy or immunotherapy.

Original languageEnglish (US)
Pages (from-to)193-207
Number of pages15
JournalTrends in Immunology
Volume37
Issue number3
DOIs
StatePublished - Mar 1 2016

Fingerprint

Indoleamine-Pyrrole 2,3,-Dioxygenase
Tumor Microenvironment
Inflammation
Immunotherapy
Regulatory T-Lymphocytes
Neoplasms
T-Lymphocytes
PTEN Phosphohydrolase
Peripheral Tolerance
Self Tolerance
DNA
Immunosuppressive Agents
Autoimmunity

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

IDO in the Tumor Microenvironment : Inflammation, Counter-Regulation, and Tolerance. / Munn, David H.; Mellor, Andrew L.

In: Trends in Immunology, Vol. 37, No. 3, 01.03.2016, p. 193-207.

Research output: Contribution to journalReview article

@article{a674804ae7d14f3aab5d865d56084699,
title = "IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance",
abstract = "Indoleamine 2,3-dioxygenase (IDO) has immunoregulatory roles associated with tryptophan metabolism. These include counter-regulation (controlling inflammation) and acquired tolerance in T cells. Recent findings reveal that IDO can be triggered by innate responses during tumorigenesis, and also by attempted T cell activation, either spontaneous or due to immunotherapy. Here we review the current understanding of mechanisms by which IDO participates in the control of inflammation and in peripheral tolerance. Focusing on the tumor microenvironment, we examine the role of IDO in response to apoptotic cells and the impact of IDO on Treg cell function. We discuss how the counter-regulatory and tolerogenic functions of IDO can be targeted for cancer immunotherapy and present an overview of the current clinical progress in this area. IDO can be induced in the tumor microenvironment by the spontaneous inflammation and T cell activation associated with many tumors; however, IDO may also be induced reactively, in response to inflammation induced by antitumor immunotherapy.IDO is rapidly induced when mice are challenged with apoptotic cells. Inhibiting or genetically deleting IDO results in loss of self-tolerance to apoptotic cell-associated antigens, and susceptibility to lupus-like autoimmunity.DNA-containing nanoparticles can induce immunosuppressive IDO via a pathway dependent on the STING sensor of cytosolic DNA.When Treg cells are activated in the presence of IDO, they upregulate a highly suppressive phenotype driven by the PTEN lipid phosphatase. In vivo, challenge with apoptotic cells triggers IDO-mediated induction of PTEN-expressing Treg cells.In tumors, IDO induction by apoptotic cells may become relevant as the tumor attempts to inhibit immune responses to dying tumor cells following chemotherapy or immunotherapy.",
author = "Munn, {David H.} and Mellor, {Andrew L.}",
year = "2016",
month = "3",
day = "1",
doi = "10.1016/j.it.2016.01.002",
language = "English (US)",
volume = "37",
pages = "193--207",
journal = "Trends in Immunology",
issn = "1471-4906",
publisher = "Elsevier Limited",
number = "3",

}

TY - JOUR

T1 - IDO in the Tumor Microenvironment

T2 - Inflammation, Counter-Regulation, and Tolerance

AU - Munn, David H.

AU - Mellor, Andrew L.

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Indoleamine 2,3-dioxygenase (IDO) has immunoregulatory roles associated with tryptophan metabolism. These include counter-regulation (controlling inflammation) and acquired tolerance in T cells. Recent findings reveal that IDO can be triggered by innate responses during tumorigenesis, and also by attempted T cell activation, either spontaneous or due to immunotherapy. Here we review the current understanding of mechanisms by which IDO participates in the control of inflammation and in peripheral tolerance. Focusing on the tumor microenvironment, we examine the role of IDO in response to apoptotic cells and the impact of IDO on Treg cell function. We discuss how the counter-regulatory and tolerogenic functions of IDO can be targeted for cancer immunotherapy and present an overview of the current clinical progress in this area. IDO can be induced in the tumor microenvironment by the spontaneous inflammation and T cell activation associated with many tumors; however, IDO may also be induced reactively, in response to inflammation induced by antitumor immunotherapy.IDO is rapidly induced when mice are challenged with apoptotic cells. Inhibiting or genetically deleting IDO results in loss of self-tolerance to apoptotic cell-associated antigens, and susceptibility to lupus-like autoimmunity.DNA-containing nanoparticles can induce immunosuppressive IDO via a pathway dependent on the STING sensor of cytosolic DNA.When Treg cells are activated in the presence of IDO, they upregulate a highly suppressive phenotype driven by the PTEN lipid phosphatase. In vivo, challenge with apoptotic cells triggers IDO-mediated induction of PTEN-expressing Treg cells.In tumors, IDO induction by apoptotic cells may become relevant as the tumor attempts to inhibit immune responses to dying tumor cells following chemotherapy or immunotherapy.

AB - Indoleamine 2,3-dioxygenase (IDO) has immunoregulatory roles associated with tryptophan metabolism. These include counter-regulation (controlling inflammation) and acquired tolerance in T cells. Recent findings reveal that IDO can be triggered by innate responses during tumorigenesis, and also by attempted T cell activation, either spontaneous or due to immunotherapy. Here we review the current understanding of mechanisms by which IDO participates in the control of inflammation and in peripheral tolerance. Focusing on the tumor microenvironment, we examine the role of IDO in response to apoptotic cells and the impact of IDO on Treg cell function. We discuss how the counter-regulatory and tolerogenic functions of IDO can be targeted for cancer immunotherapy and present an overview of the current clinical progress in this area. IDO can be induced in the tumor microenvironment by the spontaneous inflammation and T cell activation associated with many tumors; however, IDO may also be induced reactively, in response to inflammation induced by antitumor immunotherapy.IDO is rapidly induced when mice are challenged with apoptotic cells. Inhibiting or genetically deleting IDO results in loss of self-tolerance to apoptotic cell-associated antigens, and susceptibility to lupus-like autoimmunity.DNA-containing nanoparticles can induce immunosuppressive IDO via a pathway dependent on the STING sensor of cytosolic DNA.When Treg cells are activated in the presence of IDO, they upregulate a highly suppressive phenotype driven by the PTEN lipid phosphatase. In vivo, challenge with apoptotic cells triggers IDO-mediated induction of PTEN-expressing Treg cells.In tumors, IDO induction by apoptotic cells may become relevant as the tumor attempts to inhibit immune responses to dying tumor cells following chemotherapy or immunotherapy.

UR - http://www.scopus.com/inward/record.url?scp=84959292227&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959292227&partnerID=8YFLogxK

U2 - 10.1016/j.it.2016.01.002

DO - 10.1016/j.it.2016.01.002

M3 - Review article

C2 - 26839260

AN - SCOPUS:84959292227

VL - 37

SP - 193

EP - 207

JO - Trends in Immunology

JF - Trends in Immunology

SN - 1471-4906

IS - 3

ER -